Inverness expands UK presence
This article was originally published in The Gray Sheet
Executive Summary
Inverness Medical Innovations acquires UK-based distributor of lab and point-of-care diagnostics Bio-Stat for $33.4 million. Announced Oct. 3, the deal includes up to $14.6 million in additional payments, based on Bio-Stat's 2007 financial performance. The acquisition is the latest in a series of Inverness deals aimed at building the firm's worldwide distribution capabilities (1"The Gray Sheet" Sept. 3, 2007, p. 9)
You may also be interested in...
Inverness international expansion effort continues
Inverness continues to expand its international presence by acquiring Australian diagnostics firm Panbio for $37 million, the firm announces Oct. 8. Panbio makes tests for flaviviruses and other arthropod-borne viruses. "Panbio's position in the dengue fever diagnostic market will help Inverness [respond] to the recent spread of the disease throughout South America and elsewhere," Inverness explains. The move comes just days after Inverness' purchase of UK diagnostics distributor Bio-Stat for $33.4 million (1"The Gray Sheet" Oct. 8, 2007, In Brief)
Inverness Continues 2007 Buying Spree, Adds Matritech Assets For $36 Mil.
Inverness Medical continues to build its worldwide distribution capabilities with the $36 million purchase of Matritech's assets, the firm's tenth acquisition or joint venture announced this year
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”